

Electronic Supporting Information:

**Coumarin-based fluorescent probe for recognition of Cu²⁺
and for fast detection of histidine in hard-to-transfer cells by
sensing ensemble approach**

Qi-Hua You,^a Albert Wai-Ming Lee,^a Wing-Hong Chan^{*,a,b} Xiao-Ming Zhu^a and Ken Cham-Fai Leung^{*a,c}

^a Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR, P. R. China. Email: whchan@life.hkbu.edu.hk; Fax: +852-3411-7348; Tel: +852-3411-7076

^b Partner State Key Laboratory of Environmental and Biological Analysis, Hong Kong Baptist University

^c Institute of Molecular Functional Materials, University Grants Committee, Hong Kong SAR, P. R. China

Table of contents

		Page
	Experimental	3-4
	Synthesis	5
Fig. S1	¹ H-NMR spectrum of CAQA .	6
Fig. S2	Partial ¹ H-NMR spectrum (6.3 – 10.5 ppm) of CAQA .	6
Fig. S3	¹³ C-NMR spectrum of CAQA .	7
Fig. S4	MALDI-TOF HRMS spectrum of CAQA .	7
Fig. S5	Fluorescence intensity of CAQA (5 μM) upon addition of different cations.	8
Fig. S6	Absorption spectra of CAQA (5 μM) upon addition of different cations.	8
Fig. S7	Fluorescence spectra of CAQA (5 μM) upon addition of Cu ²⁺ .	9
Fig. S8	Job's plot experiment for determining the stoichiometry of CAQA and Cu ²⁺ .	9
Fig. S9	MALDI-TOF HRMS of CAQA + Cu(ClO ₄) ₂ .	10
Fig. S10	Fluorescence response ratio of CAAQ -Cu ²⁺ (5 μM) towards 20 equiv of various analytes.	10
Fig. S11	Job's plot for determining the stoichiometry of CAQA -Cu ²⁺ ensemble and histidine.	11
Fig. S12	Fluorescence titration spectra of CAQA -Cu ²⁺ ensemble (5 μM) upon the addition of histidine.	11
Fig. S13	Partial ¹ H-NMR titration spectrum (6 – 11 ppm) of CAQA with 1 equiv. of Cu ²⁺ followed by 10 equiv. of histidine.	12
Fig. S14	Partial ¹ H-NMR titration spectrum (0 – 5.5 ppm) of CAQA with 1 equiv. of Cu ²⁺ followed by 10 equiv. of histidine.	12
Fig. S15	Fluorescence titration spectra of CAQA -Cu ²⁺ (5 μM) with Cys.	13
Fig. S16	Fluorescence titration spectra of CAQA -Cu ²⁺ (5 μM) with Hcy.	13
Fig. S17	Fluorescence titration spectra of CAQA -Cu ²⁺ (5 μM) with GSH.	14
Fig. S18	Interference experiment of CAQA -Cu ²⁺ (5 μM) with various amino acids (20 equiv) and cations (10 mM) upon addition of histidine (20 equiv).	14
Fig. S19	pH effect experiments of CAQA , CAQA -Cu ²⁺ and CAQA -Cu ²⁺ -histidine mixture.	15
Fig. S20	MTT assay of human glioblastoma cells U87MG incubated with the CAQA with and without Cu ²⁺ ion at 5 or 10 μM.	15
	Reference	15-16

Experimental

General

¹H-NMR and ¹³C-NMR spectra were recorded on a Bruker Advance-III 400 MHz Spectrometer (at 400 and 100 MHz, respectively) using trimethylsilane (TMS) as an internal standard. High resolution mass spectra were performed on a Bruker Autoflex mass spectrometer (MALDI-TOF). Fluorescence emission spectra and UV-vis spectra were collected on a PE LS55 and a Cary UV-300 spectrometer, respectively. The melting point was determined with a MEL-TEMP II melting point apparatus (uncorrected). The pH measurements were performed on a Orion 420A pH mV temperature meter with a combined glass-calomel electrode. Double-distilled water was used throughout. The excitation wavelength was 430 nm. Fluorescence lifetime was measured using a PTI Time Master Model C-720. The fluorescence quantum yield Φ_F was calculated from Equation (1):

$$\Phi_{sample} = \Phi_{standard} \frac{F_{sample} A_{standard} \eta_{sample}^2}{F_{standard} A_{sample} \eta_{standard}^2} \quad (1)$$

Where the subscripts sample and standard denote reference standard and test sample, respectively, Φ is the fluorescence quantum yield, F denotes the integral of the corrected fluorescence spectrum, A is the absorbance at the excitation wavelength, and η is the refractive index of solvent.

All reagents for synthesis were obtained commercially and were used without further purification. Solvents such as dichloromethane (DCM), ethyl acetate (EA), *n*-hexane were purchased from commercial sources and were the highest grade, dry dichloromethane was distilled in calcium hydride. Silica gel (200-300 mesh, MACHEREY-NAGEL GmbH & Co. KG) was used for column chromatography. Analytical thin-layer chromatography was performed using TLC silica gel 60 F254 (aluminium sheets, Merck KGaA). In titration experiments, all the cations in the form of perchlorate or chloride and other substrates were purchased from Sigma-Aldrich, USA and stored in a vacuum desiccator.

Sample preparation

The probe **CAQA** was dissolved in ACN as a stock solution (1 mM). Buffer solution was prepared by dissolving HEPES in water (20 mM). Slight variations in the pH of the solution were achieved by adding the minimum volumes of NaOH or HCl.

Absorption and fluorescence analysis

Absorption spectra and fluorescence emission spectra were obtained with 1.0 cm quartz cells. The detection procedures were as following: in 20% ACN-HEPES (20 mM, pH = 7.4) buffer solution containing 5 μ M **CAQA** and 5 μ M Cu²⁺, a histidine

sample was gradually titrated into the solution, the mixture was equilibrated for 30 min before measurement. The fluorescence intensity was measured simultaneously at $\lambda_{\text{ex/em}} = 430/480$ nm. The excitation and emission slits were set to 4.0 nm and 4.0 nm, respectively.

Cell culture

Human glioblastoma U87MG cells were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured with RPMI-1640 (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 $\mu\text{g/mL}$ streptomycin at 37 °C and in a humidified 5% CO₂ atmosphere.


Cellular uptake study

Five thousand U87MG cells were seeded into the wells from a 24-well plate. After 12 h incubation, the culture medium in the wells was replaced with fresh medium with **CAQA** (5 μM or 10 μM) or premixed **CAQA** and CuCl₂ (equal 5 μM or 10 μM for each). After 30 min incubation, the cells were washed and fixed with 4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA), and the fluorescence of cells was observed by a Nikon TE2000 fluorescence microscope through GFP channel. In another experiment, cells were pre-treated with *N*-ethyl maleimide (20 μM) and lipofectamine 2000 (4 $\mu\text{L/mL}$).¹

Cytotoxicity study

The MTT assay was performed to determine cell viability. Five thousand U87MG cells were seeded into the wells from the 96-well plates.² After 12 h incubation, the medium in the wells was replaced with fresh medium with **CAQA** (5 μM or 10 μM) or premixed **CAQA** and CuCl₂ (5 μM or 10 μM equimolar for each). After 24 h incubation, 10 μL of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) solution (5 mg/mL) was added to each well. After 3 h incubation, the medium was removed and formazan crystals were dissolved with 150 μL DMSO for 10 min on a shaker. The absorbance of each well was measured by a microplate reader at a wavelength of 540 nm. The relative cell viability (%) for each sample related to control well was calculated.

Synthesis



To a solution of **1** (50 mg, 0.19 mmol), **2** (38 mg, 0.19 mmol) HOBt (26 mg, 0.19 mmol) and EDC (45 mg, 0.23 mmol) in dry DCM (4 mL) under N₂ atmosphere was added TEA (0.1 mL, 0.72 mmol) and the reaction mixture was stirred at r.t. overnight. H₂O (10 mL) was added to the reaction mixture and the aqueous phase was extracted with EA (2 × 10 mL). The organic phases were combined and washed with brine (10 mL) and dried with Na₂SO₄. After removal of solvent, the residue was purified by column chromatography on silica gel (DCM : EA = 5 : 1) to afford 74 mg of **CAQA** as a yellow solid. Yield: 88%.

m. p.: 217-218°C.

¹H-NMR (400 MHz, CDCl₃): δ 10.30 (1H, s), 9.49 (1H, t, *J* = 5.8 Hz), 8.79 (1H, dd, *J* = 7.1 Hz, *J* = 1.9 Hz), 8.76 (1H, s), 8.74 (1H, dd, *J* = 4.2 Hz, *J*' = 1.7 Hz), 8.14 (1H, dd, *J* = 8.3 Hz, *J*' = 1.7 Hz), 7.56-7.49 (2H, m), 7.45 (1H, d, *J* = 9.0 Hz), 7.41 (1H, dd, *J* = 8.3 Hz, *J*' = 4.2 Hz), 6.67 (1H, dd, *J* = 9.0 Hz, *J*' = 2.4 Hz), 6.54 (1H, d, *J* = 2.2 Hz), 4.46 (2H, d, *J* = 5.8 Hz), 3.48 (4H, q, *J* = 7.1 Hz), 1.26 (6H, t, *J* = 7.1 Hz).

¹³C-NMR (100 MHz, CDCl₃): δ 167.4, 164.0, 162.6, 157.9, 152.8, 148.6, 148.4, 138.6, 136.2, 134.1, 131.3, 127.9, 127.3, 121.7, 121.5, 116.7, 110.0, 109.7, 108.4, 96.7, 45.1, 44.8, 12.4.

HRMS(MALDI-TOF): *m/z* calcd. for C₂₅H₂₄N₄O₄: [M+H⁺] = 445.1870, found: 445.1248, [M+Na⁺] = 467.1690, found: 467.1665.




Fig. S1 ^1H -NMR spectrum of CAQA.




Fig. S2 Partial ^1H -NMR spectrum (6.3 – 10.5 ppm) of CAQA.




Fig. S3 ^{13}C -NMR spectrum of CAQA.




Fig. S4 MALDI-TOF HRMS spectrum of CAQA.




Fig. S5 Fluorescence intensity of CAQA (5 μM) in 20% ACN-HEPES (20 mM, pH=7.4) upon addition of different cations (1 equiv.).




Fig. S6 Absorption spectra of CAQA (5 μM) in 20% ACN-HEPES (20 mM, pH=7.4) upon addition of different cations (1 equiv.).




Fig. S7 Fluorescence spectra of **CAQA** (5 μM) in 20% ACN-HEPES (20 mM, pH = 7.4) upon addition of Cu^{2+} . Inset: Plot of fluorescence intensity at 480 nm of **CAQA** (5 μM) versus the concentration of Cu^{2+} .




Fig. S8 Job's plot for determining the stoichiometry of **CAQA** and Cu^{2+} in 20% ACN-HEPES (20 mM, pH 7.4). The total concentration of **CAQA** and Cu^{2+} was 5 μM , where $\chi_{\text{Cu}} = [\text{Cu}^{2+}]/([\text{Cu}^{2+}] + [\text{CAQA}])$.

Prof. Chan

HONG KONG BAPTIST UNIVERSITY, DEPARTMENT OF CHEMISTRY (MALDI-TOF)




Fig. S9 MALDI-TOF HRMS of CAQA + Cu(ClO₄)₂.




Fig. S10 Fluorescence response ratio of CAAQ-Cu²⁺ ensemble (5 μM) towards 20 equiv of various bio-analytes.




Fig. S11 Job's plot for determining the stoichiometry of CAQA-Cu²⁺ ensemble and histidine in 20% ACN-HEPES (20 mM, pH 7.4). The total concentration of CAQA-Cu²⁺ ensemble and Histidine was 5 μM, where $\chi_{\text{His}} = [\text{histidine}]/([\text{histidine}] + [\text{CAQA-Cu}^{2+}])$.




Fig. S12 Fluorescence spectra of CAQA-Cu²⁺ ensemble (5 μM) in 20% ACN-HEPES (20 mM, pH 7.4) upon the addition of histidine.




Fig. S13 Partial ¹H-NMR titration spectrum (6 – 11 ppm) of **CAQA** in ACN-*d*₄ with 1 equiv. of Cu²⁺ followed by 10 equiv. of histidine.




Fig. S14 Partial ¹H-NMR titration spectrum (0 – 5.5 ppm) of **CAQA** in ACN-*d*₄ with 1 equiv. of Cu²⁺ followed by 10 equiv. of histidine.




Fig. S15 Fluorescence spectra of **CAQA** (5 μM) in the presence of 1 equiv of Cu^{2+} upon the addition of Cys. Inset: Plot of fluorescence intensity at 480 nm of **CAQA** (5 μM) in the presence of 1 equiv of Cu^{2+} versus the concentration of Cys.




Fig. S16 Fluorescence spectra of **CAQA** (5 μM) in the presence of 1 equiv of Cu^{2+} upon the addition of Hcy. Inset: Plot of fluorescence intensity at 480 nm of **CAQA** (5 μM) in the presence of 1 equiv of Cu^{2+} versus the concentration of Hcy.




Fig. S17 Fluorescence spectra of **CAQA** (5 μM) in the presence of 1 equiv of Cu^{2+} upon the addition of GSH. Inset: Plot of fluorescence intensity at 480 nm of **CAQA** (5 μM) in the presence of 1 equiv of Cu^{2+} versus the concentration of GSH.




Fig. S18 Fluorescence response ratio of **CAQA-Cu²⁺** ensemble (5 μM) in the presence of various amino acids (20 equiv), biothiols-NEM adducts (20 equiv) and cations (Na^+ , K^+ , Ca^{2+} , Mg^{2+} : 10 mM) upon addition of histidine (20 equiv).




Fig. S19 Plot of fluorescence intensity at 480 nm of CAQA (5 μM) (Square), CAQA-Cu²⁺ ensemble (5 μM) (Circle) and CAQA-Cu²⁺-histidine (1:1:20) (Triangle) in 20% ACN-HEPES(20 mM) as a function of pH, respectively.




Fig. S20 MTT cell viability of human glioblastoma cells U87MG incubated with the CAQA with and without Cu²⁺ ion at 5 or 10 μM .

Reference:

- (a) S.-H. Xuan, S.-F. Lee, J. T.-F. Lau, X. Zhu, Y.-X. J. Wang, F. Wang, J. M. Y. Lai, K. W. Y. Sham, P.-C. Lo, J. C. Yu, C. H. K. Cheng and K. C.-F. Leung, *ACS Appl. Mater. Interfaces*, 2012, **4**, 2033. (b) S.-F. Lee, X.-M. Zhu, Y.-X. J. Wang, S.-H. Xuan, Q. You, W.-H. Chan, C.-H. Wong, F. Wang, J. C. Yu, C. H. K. Cheng and K. C.-F. Leung, *ACS Appl. Mater. Interfaces*, 2013, **5**, 1566. (c) K. C.-F. Leung, C.-P. Chak, S.-F. Lee, J. M. Y. Lai, X.-M. Zhu, Y.-X. J. Wang, K. W. Y. Sham, C.-H. Wong and C. H. K. Cheng, *Chem. Asian J.*, 2013, **8**, 1760. (d) D.-W. Wang, X.-M. Zhu, S.-F. Lee, H.-M. Chan, H.-W. Li, S. K. Kong, J. C. Yu, C. H. K. Cheng, Y.-X. J. Wang and K. C.-F. Leung, *J. Mater. Chem. B*, 2013, **1**, 2934. (e) K. C.-

- F. Leung, S.-F. Lee, C.-H. Wong, C.-P. Chak, J. M. Y. Lai, X.-M. Zhu, Y.-X. J. Wang, K. W. Y. Sham and C. H. K. Cheng, *Methods*, 2013, **64**, 315.
- 2 (a) X.-M. Zhu, Y.-X. J. Wang, K. C.-F. Leung, S.-F. Lee, F. Zhao, D.-W. Wang, J. M. Y. Lai, C. Wan, C. H. K. Cheng and A. T. Ahuja, *Int. J. Nanomed.*, 2012, **7**, 953. (b) X.-M. Zhu, J. Yuan, K. C.-F. Leung, S.-F. Lee, K. W. Y. Sham, C. H. K. Cheng, D. W. T. Au, G.-J. Teng, A. T. Ahuja and Y.-X. J. Wang, *Nanoscale*, 2012, **4**, 5744. (c) K. C.-F. Leung, C.-P. Chak, S.-F. Lee, J. M. Y. Lai, X.-M. Zhu, Y.-X. J. Wang, K. W. Y. Sham and C. H. K. Cheng, *Chem. Commun.*, 2013, **49**, 549. (d) W. K. W. Ho, S.-F. Lee, C.-H. Wong, X.-M. Zhu, C.-S. Kwan, C.-P. Chak, P. M. Mendes, C. H. K. Cheng and K. C.-F. Leung, *Chem. Commun.*, 2013, **49**, 10781.